In a major regulatory enforcement action protecting consumer health on October 22, 2026, the Food Safety and Standards Authority of India (FSSAI) issued official compliance notices to major food and nutraceutical manufacturers—including Nestlé and Zydus—over unsubstantiated and misleading health claims. The statutory intervention specifically flagged marketing campaigns and product packaging asserting that specialized nutritional supplements and oligosaccharide additives directly enhance infant and child immune defenses without adequate clinical substantiation. FSSAI regulatory officers emphasized that under national food safety laws, commercial entities are strictly prohibited from making implied medical claims that confuse everyday dietary products with therapeutic healthcare solutions. The regulatory body instructed the affected food corporations to immediately modify product labels, withdraw non-compliant advertisement materials, and submit verified scientific trial data supporting any functional health claims. Consumer rights organizations and public health researchers commended the strict enforcement measure, observing that transparent labelling enforcement deters deceptive commercial practices, protects consumer finances, and ensures that nutritional products meet rigorous safety and evidence standards across national retail markets.

Apex Food Regulator Takes Action Against Deceptive Labeling

In a major consumer protection enforcement drive, the Food Safety and Standards Authority of India (FSSAI) issued statutory regulatory compliance notices to prominent packaged food and beverage manufacturers across the country for making unverified "immunity-boosting" and "disease-prevention" claims on product labels and advertisement campaigns.

The regulatory crackdown follows widespread monitoring by FSSAI's Central Advisory Committee and its specialized Panel on Advertising and Claims. The authority noted that multiple brand owners continue to leverage unsubstantiated health claims—promising instant protection against viral infections, boosted cellular immunity, or guaranteed health fortification—without securing prior scientific clearance or providing clinical trial validation.

Overview: Key Operational Parameters of the FSSAI Enforcement Notice

Enforcement ParameterOfficial Statutory Specifications & Directives
Regulatory AuthorityFood Safety and Standards Authority of India (FSSAI)
Governing RegulationFSS (Advertising and Claims) Regulations, 2018 & FSS Act, 2006
Target Product CategoriesPackaged juices, dairy drinks, health supplements, herbal tea blends
Compliance Window14 Days (To submit clinical proof or modify labels/ads)
Penalty ProvisionFines up to ₹10 Lakhs & suspension of manufacturing licenses
Enforcement ScopePan-India print, digital, television, and on-pack packaging claims

Strict Adherence to Claims and Advertising Standards

Under the Food Safety and Standards (Advertising and Claims) Regulations, 2018, manufacturers are strictly prohibited from using terms such as "immunity booster," "100% protection," or "disease cure" unless supported by established scientific consensus or explicit regulatory approvals.

FSSAI Regulatory Compliance Pipeline: ------------------------------------- Market Surveillance & Label Audit ──> Show-Cause Notice Issued ──> 14-Day Scientific Validation Window ──> Label Correction or Penalty / License Suspension

FSSAI highlighted that while certain natural ingredients (such as Vitamin C, Zinc, or traditional botanicals) possess general health-supporting properties, attributing immediate therapeutic or disease-fighting capabilities to commercial packaged food products misleads consumers and violates advertising standards.

"Food business operators cannot use exaggerated health or immunity claims to influence consumer choices without robust, scientifically validated evidence. Misleading advertising compromises public trust and violates statutory food safety laws." — FSSAI Senior Official Statement

Penalties and Digital Enforcement Directives

The notices require affected brands to respond within 14 days with peer-reviewed scientific proof supporting their claims. Failure to provide adequate justification will result in immediate directives to withdraw non-compliant advertisement campaigns and modify product packaging.

Continued non-compliance attracts stringent financial penalties of up to ₹10 lakh under Section 53 of the Food Safety and Standards Act, 2006, alongside potential suspension or cancellation of manufacturing licenses. FSSAI has also alerted major e-commerce and quick-commerce platforms to audit product listings and remove misleading health claims from their online storefronts.